grant
Exploring DNA damage response pathways as targets for cancer therapy
Organization UNIVERSITY OF TX MD ANDERSON CAN CTRLocation HOUSTON, UNITED STATESPosted 1 Sept 2022Deadline 31 Aug 2029
NIHUS FederalResearch GrantFY2025AccelerationAffectBRCA 1/2 mutationsBRCA mutantsBRCA mutationsBRCA1/2 mutationsBRCA1/2mutBRCAmutCRISPR editing screenCRISPR screenCRISPR-based screenCRISPR/Cas9 screenCancer PatientCancer TreatmentCell Cycle CheckpointCell Growth in NumberCell MultiplicationCell ProliferationCellular ProliferationClinical TrialsDNA DamageDNA Damage RepairDNA InjuryDNA RepairDNA mutationDefectDevelopmentGenesGenetic ChangeGenetic defectGenetic mutationGenome InstabilityGenomic InstabilityGoalsImmune TargetingIn VitroKnowledgeMMR deficiencyMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMismatch Repair DeficiencyMutationOncogenesisPARP InhibitorPARP-1 inhibitorPARPiPathway interactionsPoly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) polymerase 1 inhibitorProliferatingProteinsUnscheduled DNA Synthesisanti-cancer immunotherapyanti-cancer therapyanti-cancer treatmentanticancer immunotherapycancer immunotherapycancer microenvironmentcancer therapycancer-directed therapycell cycle check pointclustered regularly interspaced short palindromic repeats screendesigndesigningdevelopmentalgene repairgenome mutationimmune check pointimmune checkpointimmune-based cancer therapiesimmunecheckpointimmunotherapy for cancerimmunotherapy of cancerimproved outcomein vivoinhibitormutations in BRCAnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypathwayresponsesuccesstargeted cancer therapytreatment strategytumortumor microenvironmenttumorigenesis
Description preview
Project Summary:
It is well established that defects in DNA damage response (DDR) pathways accelerate tumorigenesis.
Significant efforts have been devoted to target defective DDR pathways to improve outcome for cancer patients.
These efforts led to the FDA’s approval of PARP inhibitors for the treatment of cancers carrying BRCA1/2
mutations and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click